Inclusion Criteria : 
  -  Participant with moderate to severe Hidradenitis Suppurativa ( HS ) for at least one year prior to Baseline visit . 
  -  HS lesions present in at least two distinct anatomical areas . 
  -  Draining fistula count of <  =  20 at Baseline visit . 
  -  Total abscesses and nodule count ( AN count ) of >  =  5 at Baseline visit . 
  -  Participants are required to use a daily antiseptic wash on their HS lesions  . 
  -  Participant must have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for treatment of HS . 
Exclusion Criteria : 
  -  Participant has a history of active skin disease other than HS that could interfere with the assessment of HS . 
  -  Participant has active tuberculosis ( TB ) or concurrent treatment for latent TB or evidence of hepatitis B virus ( HBV ) or hepatitis C virus ( HCV ) or human immuno deficiency virus ( HIV ) infection . 
  -  Participant has prior exposure to anti - interleukin -  1 ( anti - IL -  1 ) treatment within  3 months or  5 half - lives , whichever is longer , prior to baseline . 
  -  Participant has received prescription topical therapies ( including topical antibiotics ) within  14 days prior to the Baseline visit . 
  -  Participant has received systemic non - biologic therapies that can also be used to treat HS within  4 weeks prior to the Baseline visit . 
  -  Participant has received any systemic ( including oral ) antibiotic treatment within  4 weeks prior to the Baseline visit .